quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:12:11·45d
INSIDERFiling
Agios Pharmaceuticals Inc. logo

Chief Corp Dev & Strategy Viswanadhan Krishnan sold $82,260 worth of shares (2,959 units at $27.80) and converted options into 8,100 shares (SEC Form 4)

AGIO· Agios Pharmaceuticals Inc.
Health Care
Original source

Companies

  • AGIO
    Agios Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Apr 20UpdateH.C. Wainwright$50.00
  • Nov 24UpdateTruist-
  • Nov 20UpdateLeerink Partners$34.00
  • Nov 19UpdateRBC Capital Mkts$28.00
  • Feb 24UpdateH.C. Wainwright$58.00
  • Oct 16UpdateScotiabank-

Related

  • ANALYST4d
    H.C. Wainwright reiterated coverage on Agios Pharma with a new price target
  • INSIDER17d
    SEC Form 4 filed by Burns James William
  • INSIDER17d
    SEC Form 4 filed by Gheuens Sarah
  • INSIDER17d
    SEC Form 4 filed by Jones Cecilia
  • INSIDER17d
    SEC Form 4 filed by Milanova Tsveta
  • INSIDER17d
    SEC Form 4 filed by Viswanadhan Krishnan
  • INSIDER17d
    SEC Form 4 filed by Goff Brian
  • PR18d
    Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022